ArticleAntimicrobial agents and chemotherapy2020
Distinct Mechanisms of Dissemination of NDM-1 Metallo-β-Lactamase in
Open access · greenAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Surveillance of antibiotic-resistant bacteria integrating whole genome sequencing and epidemiological information - a global, systematic review, 2012-2023.Antimicrobial resistance and infection control · 2026Pooled it
- Vitamin B12 promotes cefiderocol resistance and small-colony variants in carbapenem-resistantmBio · 2026Article
- Next-Gen Nano Biosensor Technologies to Monitor Carbapenem Resistance for Personalized Medicine.Indian journal of microbiology · 2025Article
- Emergence of NDM-1 on IncR-IncFIA (HI1) plasmid in carbapenem-resistantFrontiers in microbiology · 2025Article
- Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistantMicrobiology spectrum · 2024Article
- Carbapenem-resistant Acinetobacter baumannii (CRAB): metabolic adaptation and transcriptional response to human urine (HU).Scientific reports · 2024Article
- Carbapenem-resistant Acinetobacter baumannii (CRAB): metabolic adaptation and transcriptional response to human urine (HU).Research square · 2024Article
- Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistantbioRxiv : the preprint server for biology · 2024Article
- Article
- Multiple host colonization and differential expansion of multidrug-resistant ST25-Acinetobacter baumannii clades.Scientific reports · 2023Article
- Antimicrobial activity of the Lacticaseibacillus rhamnosus CRL 2244 and its impact on the phenotypic and transcriptional responses in carbapenem resistant Acinetobacter baumannii.Scientific reports · 2023Article
- Induced Heteroresistance in Carbapenem-ResistantInternational journal of molecular sciences · 2023Article
- Article
- Article
- The Iron Content of Human Serum Albumin Modulates the Susceptibility ofBiomedicines · 2023Article
- Genomic characterization of an NDM-9-producingFrontiers in microbiology · 2023Article
- Acinetobacter baumannii response to cefiderocol challenge in human urine.Scientific reports · 2022Article
- Human Serum Proteins and Susceptibility ofBiomedicines · 2022Article
- A case-control study of infections caused byFrontiers in cellular and infection microbiology · 2022Article
- Genetic Configuration of Genomic Resistance Islands inFrontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Mark D AdamsThe Jackson Laboratory, Farmington, Connecticut, USA.ORCID 0000-0003-3161-7460
Fernando PasteranNational/Regional Reference Laboratory for Antimicrobial Resistance (NRL), Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina.
German M TragliaDepartamento de Desarrollo Biotecnología, Instituto de Higiene, Facultad de Medicina, Universidad de La República, Montevideo, Uruguay.
Jasmine MartinezCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, California, USA.
Fanny HuangCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, California, USA.
Christine LiuCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, California, USA.
Jennifer S FernandezCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, California, USA.
Carolina LopezInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR), Rosario, Argentina.
Lisandro J GonzalezInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR), Rosario, Argentina.
Ezequiel AlbornozNational/Regional Reference Laboratory for Antimicrobial Resistance (NRL), Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina.
Alejandra CorsoNational/Regional Reference Laboratory for Antimicrobial Resistance (NRL), Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr. Carlos G. Malbrán, Buenos Aires, Argentina.
Alejandro J VilaInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR), Rosario, Argentina.
Robert A BonomoResearch Service and GRECC, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Maria Soledad RamirezCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, California, USA msramirez@fullerton.edu.ORCID 0000-0002-9904-7890
California State University, Fullerton · USAdministración Nacional de Laboratorios e Institutos de Salud · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARGeriatric Research Education and Clinical Center · USJackson Laboratory · USUniversidad de la República de Uruguay · UY
Funding
Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MIdentifying host human products responsible for natural transformation of resistance traits in Acinetobacter sppSC3GM125556 · NIGMS · CALIFORNIA STATE UNIVERSITY FULLERTON · PI RAMIREZ, MARIA SOLEDAD · 2018 to 2025
$851kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIGMS NIH HHS SC3 GM125556
Abstract
A 4-year surveillance of carbapenem-resistant
Indexed as
Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsArgentinabeta-LactamasesCarbapenemsGenome, BacterialHumansMicrobial Sensitivity TestsPlasmidsAnti-Bacterial Agentsbeta-lactamase NDM-1beta-LactamasesCarbapenemsAcinetobacterAcinetobacter baumanniicarbapenem resistancecarbapenemsNDM-1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.